原发免疫性血小板减少症免疫机制及免疫治疗的研究进展

Research Progress on Immune Mechanism and Immunotherapy of Primary Immune Thrombocytopenia

原发免疫性血小板减少症(ITP)是一种自身免疫性疾病。ITP的发病机制复杂,其中B细胞、T细胞及DC细胞所致机体免疫功能失调是主要原因。针对不同免疫发病机制,有不同的治疗靶点,免疫抑制剂作为二线性治疗方案应用越来越多。来那度胺和硼替佐米具有免疫作用,已用于恶性血液病的治疗,但对于ITP的疗效有待研究。本文就ITP免疫机制不同方面及不同治疗药物的研究进展进行综述,讨论来那度胺和硼替佐米等药物在ITP治疗中的应用情况,以期为治疗ITP提供相关临床经验。

Primary immune thrombocytopenia(ITP)is an autoimmune disease.The pathogenesis of ITP is complex,among which the immune dysfunction caused by B cells,T cells and DC cells is the main reason.For different immune pathogenesis,there are different therapeutic targets,and immunosuppressants are used more and more as a second-line therapy.Lenalidomide and bortezomib have immunological effects and have been used in the treatment of hematological malignancies,but whether they have efficacy in ITP remains to be studied.This article reviews the research progress of different aspects of ITP immune mechanism and different therapeutic drugs,and discusses the application of drugs such as lenalidomide and bortezomib in the treatment of ITP,in order to provide relevant clinical experience for the treatment of ITP.